“Understanding Placebo Response and Patient Personality” Outsourcing-Pharma Article
A representative from Tools4Patient discusses how grasping the ties between the two can help in reducing the impact of the placebo response in trials.
News
News
News
Tools4Patient Proves Performance of Novel Technology to Predict Placebo Response in Osteoarthritis Clinical Trials
Belgian startup Tools4Patient recently presented data showing its novel technology Placebell©™ predicted placebo response in a Phase 2 randomized controlled trial (RCT) for osteoarthritis (OA). Placebell is the first robust technology using predictive modeling that is proven to reduce the impact of the placebo response in clinical trials under real-world conditions. Data from the Phase 2 RCT, “Predicting the Placebo Response in OA to Improve the Precision of the Treatment Effect Estimation,” was presented as a late-breaking abstract at the OARSI Connect Virtual World Congress on Osteoarthritis on April 29, 2021. This innovation by Tools4Patient is a major advancement for increasing clinical study success and reducing drug development costs and timelines.
News
Tools4Patient Adds Quality Assurance Director To Team
The addition of Delphine to T4P’s expanding team reflects the company’s commitment to building and maintaining a robust quality program, which is central to its goal of being a trusted partner providing predictive tools to biopharmaceutical companies. Delphine works with T4P’s operational and scientific groups to support software and clinical-related activities for programs conducted with sponsors or as part of the company’s R&D activities.
News
“Stratification of patients based on the neuropathic pain symptom inventory (NPSI): development and validation of a new algorithm” published in Pain.
The journal article “Stratification of patients based on the neuropathic pain symptom inventory (NPSI): development and validation of a new algorithm”, has been published ahead of print in the journal Pain. This article was authored by Didier Bouhassira, MD, Director of Research at the National Institute for Health and Medical Research (INSERM) in France and member of Tools4Patient’s scientific advisory board, and was co-authored by Tools4Patient scientists Samuel Branders PhD, Alvaro Pereira PhD and Dominique Demolle, PhD.
News
The Placebo Response: A Hidden Risk to COVID-19 Trials” – First Opinion written by Tools4Patient authors published in STAT News
STAT News published “The Placebo Response: A Hidden Risk to COVID-19 Trials” written by Tools4Patient authors on October…
News
“Modeling of Peripheral Neuropathic Pain and Osteoarthritis Placebo Response” presented at the International Society for CNS Clinical Trials and Methodology
Dr. Dominique Demolle, CEO of Tools4Patient, recently presented data at the 16th Annual Scientific Meeting of the International Society for CNS…